Translation of "Hand-foot syndrome" in German

Following grade 3 hand- foot syndrome, subsequent doses of Xeloda should be decreased.

Following grade 3 hand-foot syndrome, subsequent doses of capecitabine should be decreased.

Hand-foot syndrome (HFS) (see section 4.4)

In the course of a chemotherapeutic treatment, the so-called hand-foot syndrome frequently occurs.

The most common included hand-foot syndrome, infection, vomiting, and rash.

Hand-foot syndrome (see section 4.4):

Hand-foot syndrome (see section 4.4)

The most common adverse reactions were diarrhoea, rash, alopecia and hand-foot syndrome (corresponds to palmar plantar erythrodysaesthesia syndrome in MedDRA).

Dose limiting toxicities include diarrhoea, abdominal pain, nausea, stomatitis and hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia).

When Xeloda and cisplatin are used in combination, the use of vitamin B6 (pyridoxine) is not advised for symptomatic or secondary prophylactic treatment of hand– foot syndrome, because of published reports that it may decrease the efficacy of cisplatin.

The most commonly reported and/ or clinically relevant treatment-related adverse drug reactions (ADRs) were gastrointestinal disorders (especially diarrhoea, nausea, vomiting, abdominal pain, stomatitis), hand-foot syndrome (palmar-plantar erythrodysesthesia), fatigue, asthenia, anorexia, cardiotoxicity, increased renal dysfunction on those with preexisting compromised renal function, and thrombosis/ embolism.

When capecitabine and cisplatin are used in combination, the use of vitamin B6 (pyridoxine) is not advised for symptomatic or secondary prophylactic treatment of hand-foot syndrome, because of published reports that it may decrease the efficacy of cisplatin.

Reactions were characterised by a rash including localised eruptions mainly on the feet and hands (including severe hand and foot syndrome), but also on the arms, face or thorax, and frequently associated with pruritus.

The most common side effects with Stivarga (which may affect more than 3 in 10 people) are pain, weakness, tiredness, loss of appetite and eating less, hand-foot syndrome (rash and numbness affecting the palms and soles), diarrhoea, infection and hypertension (high blood pressure).

There is some evidence that dexpanthenol is effective for hand-foot syndrome prophylaxis in patients treated with Xeloda.

In clinical studies, the most common side effects with Nexavar (seen in more than 1 patient in 10) were lymphopenia (low levels of lymphocytes, a type of white blood cell), hypophosphataemia (low levels of phosphate in the blood), haemorrhage (bleeding), hypertension (high blood pressure), diarrhoea, nausea (feeling sick), vomiting, rash, alopecia (hair loss), ‘ hand foot syndrome’ (rash and pain on the palms and soles), erythema (redness), pruritus (itchiness), fatigue (tiredness), pain, and increased amylase and lipase (enzymes produced by the pancreas).

The doctor may wish to delay the start and/ or reduce the dose of the next treatment (see Strategies to prevent and treat hand-foot syndrome, below);

If grade 2 or 3 hand- foot syndrome occurs, administration of Xeloda should be interrupted until the event resolves or decreases in intensity to grade 1.

Persistent or severe hand-foot syndrome (Grade 2 and above) can eventually lead to loss of fingerprints which could impact patient identification.

There is some evidence that dexpanthenol is effective for hand-foot syndrome prophylaxis in patients treated with Ecansya.